{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:19:42Z","timestamp":1787318382664,"version":"build-2736575974"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00296-020-04694-2","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T14:02:36Z","timestamp":1599055356000},"page":"1741-1751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-7396","authenticated-orcid":false,"given":"Durga Prasanna","family":"Misra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-6018","authenticated-orcid":false,"given":"Armen Yuri","family":"Gasparyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4188-8486","authenticated-orcid":false,"given":"Olena","family":"Zimba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"4694_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41584-019-0337-0","volume":"16","author":"KM Kingsmore","year":"2020","unstructured":"Kingsmore KM, Grammer AC, Lipsky PE (2020) Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol 16:32\u201352. https:\/\/doi.org\/10.1038\/s41584-019-0337-0","journal-title":"Nat Rev Rheumatol"},{"key":"4694_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41584-020-0375-7","volume":"16","author":"SA Kerrigan","year":"2020","unstructured":"Kerrigan SA, McInnes IB (2020) Reflections on 'older' drugs: learning new lessons in rheumatology. Nat Rev Rheumatol 16:179\u2013183. https:\/\/doi.org\/10.1038\/s41584-020-0375-7","journal-title":"Nat Rev Rheumatol"},{"key":"4694_CR3","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s10067-020-05073-9","volume":"39","author":"DP Misra","year":"2020","unstructured":"Misra DP, Agarwal V, Gasparyan AY, Zimba O (2020) Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 39:2055\u20132062. https:\/\/doi.org\/10.1007\/s10067-020-05073-9","journal-title":"Clin Rheumatol"},{"key":"4694_CR4","doi-asserted-by":"publisher","unstructured":"Suri JS, Puvvula A, Biswas M et al (2020) COVID-19 pathways for brain and heart injury in comorbidity patients: a role of medical imaging and artificial intelligence-based COVID severity classification: a review. Comput Biol Med 103960. https:\/\/doi.org\/10.1016\/j.compbiomed.2020.103960.","DOI":"10.1016\/j.compbiomed.2020.103960"},{"key":"4694_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2020.12603","volume":"324","author":"Carf\u00ec A, Bernabei R, Landi F, for the Gemelli Against Covid-Post-Acute Care Study Group","year":"2020","unstructured":"Carf\u00ec A, Bernabei R, Landi F, for the Gemelli Against Covid-Post-Acute Care Study Group (2020) Persistent symptoms in patients after acute COVID-19. JAMA 324:603\u2013605. https:\/\/doi.org\/10.1001\/jama.2020.12603","journal-title":"JAMA"},{"key":"4694_CR6","doi-asserted-by":"publisher","first-page":"m3001","DOI":"10.1136\/bmj.m3001","volume":"370","author":"E Fraser","year":"2020","unstructured":"Fraser E (2020) Long term respiratory complications of covid-19. BMJ 370:m3001. https:\/\/doi.org\/10.1136\/bmj.m3001","journal-title":"BMJ"},{"key":"4694_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, Dorner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16:155\u2013166. https:\/\/doi.org\/10.1038\/s41584-020-0372-x","journal-title":"Nat Rev Rheumatol"},{"key":"4694_CR8","doi-asserted-by":"publisher","first-page":"e0212614","DOI":"10.1371\/journal.pone.0212614","volume":"14","author":"S Miranda","year":"2019","unstructured":"Miranda S, Billoir P, Damian L et al (2019) Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. PLoS ONE 14:e0212614. https:\/\/doi.org\/10.1371\/journal.pone.0212614","journal-title":"PLoS ONE"},{"key":"4694_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/rheumatology\/kex378","volume":"57","author":"K Schreiber","year":"2018","unstructured":"Schreiber K, Breen K, Parmar K, Rand JH, Wu XX, Hunt BJ (2018) The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology (Oxford) 57:120\u2013124. https:\/\/doi.org\/10.1093\/rheumatology\/kex378","journal-title":"Rheumatology (Oxford)"},{"key":"4694_CR10","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3899\/jrheum.161351","volume":"44","author":"S Fasano","year":"2017","unstructured":"Fasano S, Pierro L, Pantano I, Iudici M, Valentini G (2017) Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol 44:1032\u20131038. https:\/\/doi.org\/10.3899\/jrheum.161351","journal-title":"J Rheumatol"},{"key":"4694_CR11","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/rheumatology\/kex357","volume":"56","author":"CY Hsu","year":"2017","unstructured":"Hsu CY, Lin YS, Su YJ et al (2017) Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study. Rheumatology (Oxford) 56:2212\u20132221. https:\/\/doi.org\/10.1093\/rheumatology\/kex357","journal-title":"Rheumatology (Oxford)"},{"key":"4694_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/0961203317724219","volume":"27","author":"D Erkan","year":"2018","unstructured":"Erkan D, Unlu O, Sciascia S et al (2018) Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus 27:399\u2013406. https:\/\/doi.org\/10.1177\/0961203317724219","journal-title":"Lupus"},{"key":"4694_CR13","doi-asserted-by":"publisher","first-page":"102491","DOI":"10.1016\/j.autrev.2020.102491","volume":"19","author":"E Kravvariti","year":"2020","unstructured":"Kravvariti E, Koutsogianni A, Samoli E, Sfikakis PP, Tektonidou MG (2020) The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. Autoimmun Rev 19:102491. https:\/\/doi.org\/10.1016\/j.autrev.2020.102491","journal-title":"Autoimmun Rev"},{"key":"4694_CR14","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","volume":"78","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou MG, Andreoli L, Limper M et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78:1296\u20131304. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215213","journal-title":"Ann Rheum Dis"},{"key":"4694_CR15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.autrev.2018.05.012","volume":"17","author":"C Belizna","year":"2018","unstructured":"Belizna C, Pregnolato F, Abad S et al (2018) HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmun Rev 17:1153\u20131168. https:\/\/doi.org\/10.1016\/j.autrev.2018.05.012","journal-title":"Autoimmun Rev"},{"key":"4694_CR16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1055\/s-0037-1603359","volume":"43","author":"K Schreiber","year":"2017","unstructured":"Schreiber K, Breen K, Cohen H et al (2017) HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 43:562\u2013571. https:\/\/doi.org\/10.1055\/s-0037-1603359","journal-title":"Semin Thromb Hemost"},{"key":"4694_CR17","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.gofs.2018.06.008","volume":"46","author":"A Mekinian","year":"2018","unstructured":"Mekinian A, Vicaut E, Cohen J, Bornes M, Kayem G, Fain O (2018) Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL. Gynecol Obstet Fertil Senol 46:598\u2013604. https:\/\/doi.org\/10.1016\/j.gofs.2018.06.008","journal-title":"Gynecol Obstet Fertil Senol"},{"key":"4694_CR18","doi-asserted-by":"publisher","first-page":"e025649","DOI":"10.1136\/bmjopen-2018-025649","volume":"9","author":"E Pasquier","year":"2019","unstructured":"Pasquier E, de Saint-Martin L, Marhic G et al (2019) Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study. BMJ Open 9:e025649. https:\/\/doi.org\/10.1136\/bmjopen-2018-025649","journal-title":"BMJ Open"},{"key":"4694_CR19","first-page":"e95","volume":"18","author":"J Zhou","year":"2013","unstructured":"Zhou J, Li G, Wang ZH, Wang LP, Dong PJ (2013) Effects of low-dose hydroxychloroquine on expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in peri-infarct myocardium in rats. Exp Clin Cardiol 18:e95\u201398","journal-title":"Exp Clin Cardiol"},{"key":"4694_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2016-209954","volume":"76","author":"G Ozen","year":"2017","unstructured":"Ozen G, Pedro S, Holmqvist ME, Avery M, Wolfe F, Michaud K (2017) Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis 76:848\u2013854. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209954","journal-title":"Ann Rheum Dis"},{"key":"4694_CR21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2147\/tcrm.S130666","volume":"13","author":"HH Chen","year":"2017","unstructured":"Chen HH, Chen DY, Lin CC, Chen YM, Lai KL, Lin CH (2017) Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis\/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. Ther Clin Risk Manag 13:583\u2013592. https:\/\/doi.org\/10.2147\/tcrm.S130666","journal-title":"Ther Clin Risk Manag"},{"key":"4694_CR22","doi-asserted-by":"publisher","first-page":"e0210459","DOI":"10.1371\/journal.pone.0210459","volume":"14","author":"S Lillegraven","year":"2019","unstructured":"Lillegraven S, Greenberg JD, Reed GW et al (2019) Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS ONE 14:e0210459. https:\/\/doi.org\/10.1371\/journal.pone.0210459","journal-title":"PLoS ONE"},{"key":"4694_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/qjmed\/hcz112","volume":"112","author":"TH Chen","year":"2019","unstructured":"Chen TH, Lai TY, Wang YH, Chiou JY, Hung YM, Wei JC (2019) Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjogren syndrome. QJM 112:757\u2013762. https:\/\/doi.org\/10.1093\/qjmed\/hcz112","journal-title":"QJM"},{"key":"4694_CR24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.acthis.2016.06.002","volume":"118","author":"AAM Abdel-Hamid","year":"2016","unstructured":"Abdel-Hamid AAM, Firgany AEL (2016) Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines. Acta Histochem 118:560\u2013573. https:\/\/doi.org\/10.1016\/j.acthis.2016.06.002","journal-title":"Acta Histochem"},{"key":"4694_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/1753-0407.12989","volume":"12","author":"SH Hsia","year":"2020","unstructured":"Hsia SH, Duran P, Lee ML, Davidson MB (2020) Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: a pilot study. J Diabetes 12:91\u201394. https:\/\/doi.org\/10.1111\/1753-0407.12989","journal-title":"J Diabetes"},{"key":"4694_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4103\/2277-9175.187401","volume":"5","author":"F Sheikhbahaie","year":"2016","unstructured":"Sheikhbahaie F, Amini M, Gharipour M, Aminoroaya A, Taheri N (2016) The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition. Adv Biomed Res 5:145. https:\/\/doi.org\/10.4103\/2277-9175.187401","journal-title":"Adv Biomed Res"},{"key":"4694_CR27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/s2213-8587(15)00328-9","volume":"3","author":"A Luthra","year":"2015","unstructured":"Luthra A, Misra A (2015) The marketing of unproven drugs for diabetes and dyslipidaemia in India. Lancet Diabetes Endocrinol 3:758\u2013760. https:\/\/doi.org\/10.1016\/s2213-8587(15)00328-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4694_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.mehy.2016.04.045","volume":"93","author":"L Sun","year":"2016","unstructured":"Sun L, Liu M, Li R et al (2016) Hydroxychloroquine, a promising choice for coronary artery disease? Med Hypotheses 93:5\u20137. https:\/\/doi.org\/10.1016\/j.mehy.2016.04.045","journal-title":"Med Hypotheses"},{"key":"4694_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","volume":"16","author":"BN Cronstein","year":"2020","unstructured":"Cronstein BN, Aune TM (2020) Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 16:145\u2013154. https:\/\/doi.org\/10.1038\/s41584-020-0373-9","journal-title":"Nat Rev Rheumatol"},{"key":"4694_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00296-016-3435-1","volume":"37","author":"DP Misra","year":"2017","unstructured":"Misra DP, Shenoy SN (2017) Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatol Int 37:151\u2013167. https:\/\/doi.org\/10.1007\/s00296-016-3435-1","journal-title":"Rheumatol Int"},{"key":"4694_CR31","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.2174\/0929867322666150415122039","volume":"22","author":"TV Popkova","year":"2015","unstructured":"Popkova TV, Novikova DS, Gasparyan AY, Nasonov EL (2015) Cardiovascular effects of methotrexate in rheumatoid arthritis revisited. Curr Med Chem 22:1903\u20131910. https:\/\/doi.org\/10.2174\/0929867322666150415122039","journal-title":"Curr Med Chem"},{"key":"4694_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.14740\/cr468w","volume":"7","author":"V Gouveia","year":"2016","unstructured":"Gouveia V, Oliveira DC, Tenorio E, Brito N, Sarinho E (2016) Percutaneous coronary intervention: safety of methotrexate and its possible benefits on restenosis after bare-metal stent deployment. Cardiol Res 7:104\u2013109. https:\/\/doi.org\/10.14740\/cr468w","journal-title":"Cardiol Res"},{"key":"4694_CR33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1177\/1074248417699884","volume":"22","author":"DM Moreira","year":"2017","unstructured":"Moreira DM, Lueneberg ME, da Silva RL, Fattah T, Gottschall CAM (2017) MethotrexaTE THerapy in ST-Segment Elevation MYocardial InfarctionS: a randomized double-blind, placebo-controlled trial (TETHYS Trial). J Cardiovasc Pharmacol Ther 22:538\u2013545. https:\/\/doi.org\/10.1177\/1074248417699884","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"4694_CR34","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker PM, Everett BM, Pradhan A et al (2019) Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 380:752\u2013762. https:\/\/doi.org\/10.1056\/NEJMoa1809798","journal-title":"N Engl J Med"},{"key":"4694_CR35","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1517\/17425255.2015.1076391","volume":"11","author":"AY Gasparyan","year":"2015","unstructured":"Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD (2015) Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 11:1781\u20131794. https:\/\/doi.org\/10.1517\/17425255.2015.1076391","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4694_CR36","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/j.1749-6632.2009.04674.x","volume":"1173","author":"A Bhat","year":"2009","unstructured":"Bhat A, Naguwa SM, Cheema GS, Gershwin ME (2009) Colchicine revisited. Ann N Y Acad Sci 1173:766\u2013773. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04674.x","journal-title":"Ann N Y Acad Sci"},{"key":"4694_CR37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","volume":"269","author":"GJ Martinez","year":"2018","unstructured":"Martinez GJ, Celermajer DS, Patel S (2018) The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis 269:262\u2013271. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.12.027","journal-title":"Atherosclerosis"},{"key":"4694_CR38","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1253\/circj.CJ-16-0949","volume":"81","author":"K Fujisue","year":"2017","unstructured":"Fujisue K, Sugamura K, Kurokawa H et al (2017) Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction. Circ J 81:1174\u20131182. https:\/\/doi.org\/10.1253\/circj.CJ-16-0949","journal-title":"Circ J"},{"key":"4694_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-020-09974-7","author":"A Cecconi","year":"2020","unstructured":"Cecconi A, Vilchez-Tschischke JP, Mateo J et al (2020) Effects of colchicine on atherosclerotic plaque stabilization: a multimodality imaging study in an animal model. J Cardiovasc Transl Res. https:\/\/doi.org\/10.1007\/s12265-020-09974-7","journal-title":"J Cardiovasc Transl Res"},{"key":"4694_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.vph.2018.09.004","volume":"111","author":"G Cimmino","year":"2018","unstructured":"Cimmino G, Tarallo R, Conte S et al (2018) Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascul Pharmacol 111:62\u201370. https:\/\/doi.org\/10.1016\/j.vph.2018.09.004","journal-title":"Vascul Pharmacol"},{"key":"4694_CR41","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3346\/jkms.2017.32.10.1588","volume":"32","author":"A Omma","year":"2017","unstructured":"Omma A, Sandikci SC, K\u00fcc\u00fcksahin O, Alisik M, Erel O (2017) Can the thiol\/disulfide imbalance be a predictor of colchicine resistance in familial mediterranean fever? J Korean Med Sci 32:1588\u20131594. https:\/\/doi.org\/10.3346\/jkms.2017.32.10.1588","journal-title":"J Korean Med Sci"},{"key":"4694_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","volume":"11","author":"K Vaidya","year":"2018","unstructured":"Vaidya K, Arnott C, Martinez GJ et al (2018) Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study. JACC Cardiovasc Imaging 11:305\u2013316. https:\/\/doi.org\/10.1016\/j.jcmg.2017.08.013","journal-title":"JACC Cardiovasc Imaging"},{"key":"4694_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijcard.2019.01.054","volume":"281","author":"M Kajikawa","year":"2019","unstructured":"Kajikawa M, Higashi Y, Tomiyama H et al (2019) Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. Int J Cardiol 281:35\u201339. https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.054","journal-title":"Int J Cardiol"},{"key":"4694_CR44","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.clinthera.2019.07.015","volume":"41","author":"B Tucker","year":"2019","unstructured":"Tucker B, Kurup R, Barraclough J et al (2019) Colchicine as a novel therapy for suppressing chemokine production in patients with an acute coronary syndrome: a pilot study. Clin Ther 41:2172\u20132181. https:\/\/doi.org\/10.1016\/j.clinthera.2019.07.015","journal-title":"Clin Ther"},{"key":"4694_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ahj.2019.06.003","volume":"215","author":"T Hennessy","year":"2019","unstructured":"Hennessy T, Soh L, Bowman M et al (2019) The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J 215:62\u201369. https:\/\/doi.org\/10.1016\/j.ahj.2019.06.003","journal-title":"Am Heart J"},{"key":"4694_CR46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ahj.2019.09.011","volume":"218","author":"SM Nidorf","year":"2019","unstructured":"Nidorf SM, Fiolet ATL, Eikelboom JW et al (2019) The effect of low-dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J 218:46\u201356. https:\/\/doi.org\/10.1016\/j.ahj.2019.09.011","journal-title":"Am Heart J"},{"key":"4694_CR47","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.acvd.2016.10.004","volume":"110","author":"M Akodad","year":"2017","unstructured":"Akodad M, Lattuca B, Nagot N et al (2017) COLIN trial: value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Arch Cardiovasc Dis 110:395\u2013402. https:\/\/doi.org\/10.1016\/j.acvd.2016.10.004","journal-title":"Arch Cardiovasc Dis"},{"key":"4694_CR48","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD et al (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381:2497\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1912388","journal-title":"N Engl J Med"},{"key":"4694_CR49","doi-asserted-by":"crossref","unstructured":"Masson W, Lobo M, Molinero G, Masson G, Lavalle-Cobo A (2020) Role of colchicine in stroke prevention: an updated meta-analysis. J Stroke Cerebrovasc Dis 104756. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2020.104756","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104756"},{"key":"4694_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clinthera.2018.08.008","volume":"41","author":"SG Deftereos","year":"2019","unstructured":"Deftereos SG, Vrachatis DA, Angelidis C et al (2019) The role of colchicine in treating postoperative and post-catheter ablation atrial fibrillation. Clin Ther 41:21\u201329. https:\/\/doi.org\/10.1016\/j.clinthera.2018.08.008","journal-title":"Clin Ther"},{"key":"4694_CR51","doi-asserted-by":"publisher","first-page":"109422","DOI":"10.1016\/j.biopha.2019.109422","volume":"119","author":"H Yue","year":"2019","unstructured":"Yue H, Liang W, Gu J et al (2019) Comparative transcriptome analysis to elucidate the therapeutic mechanism of colchicine against atrial fibrillation. Biomed Pharmacother 119:109422. https:\/\/doi.org\/10.1016\/j.biopha.2019.109422","journal-title":"Biomed Pharmacother"},{"key":"4694_CR52","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/echo.14605","volume":"37","author":"M Shojaeifard","year":"2020","unstructured":"Shojaeifard M, Pakbaz M, Beheshti R et al (2020) The effect of colchicine on the echocardiographic constrictive physiology after coronary artery bypass graft surgery. Echocardiography 37:399\u2013403. https:\/\/doi.org\/10.1111\/echo.14605","journal-title":"Echocardiography"},{"key":"4694_CR53","doi-asserted-by":"publisher","first-page":"F1466","DOI":"10.1152\/ajprenal.00057.2013","volume":"305","author":"T Guan","year":"2013","unstructured":"Guan T, Gao B, Chen G et al (2013) Colchicine attenuates renal injury in a model of hypertensive chronic kidney disease. Am J Physiol Renal Physiol 305:F1466\u20131476. https:\/\/doi.org\/10.1152\/ajprenal.00057.2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"4694_CR54","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3904\/kjim.2016.131","volume":"33","author":"S Kim","year":"2018","unstructured":"Kim S, Jung ES, Lee J, Heo NJ, Na KY, Han JS (2018) Effects of colchicine on renal fibrosis and apoptosis in obstructed kidneys. Korean J Intern Med 33:568\u2013576. https:\/\/doi.org\/10.3904\/kjim.2016.131","journal-title":"Korean J Intern Med"},{"key":"4694_CR55","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3899\/jrheum.100352","volume":"37","author":"G de Socio","year":"2010","unstructured":"de Socio G, Verrecchia E, Fonnesu C, Giovinale M, Gasbarrini GB, Manna R (2010) Effectiveness of colchicine therapy in 4 cases of retroperitoneal fibrosis associated with autoinflammatory diseases. J Rheumatol 37:1971\u20131972. https:\/\/doi.org\/10.3899\/jrheum.100352","journal-title":"J Rheumatol"},{"key":"4694_CR56","doi-asserted-by":"publisher","first-page":"e650","DOI":"10.1016\/j.bjps.2010.03.018","volume":"63","author":"A Sigler","year":"2010","unstructured":"Sigler A (2010) Use of colchicine to prevent recurrence of ear keloids. A new approach. J Plast Reconstr Aesthet Surg 63:e650\u2013652. https:\/\/doi.org\/10.1016\/j.bjps.2010.03.018","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"4694_CR57","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/njms.NJMS_5_17","volume":"8","author":"D Daga","year":"2017","unstructured":"Daga D, Singh RK, Pal US, Gurung T, Gangwar S (2017) Efficacy of oral colchicine with intralesional hyaluronidase or triamcinolone acetonide in the Grade II oral submucous fibrosis. Natl J Maxillofac Surg 8:50\u201354. https:\/\/doi.org\/10.4103\/njms.NJMS_5_17","journal-title":"Natl J Maxillofac Surg"},{"key":"4694_CR58","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1179\/016164110x12681290831487","volume":"32","author":"O Ozdemir","year":"2010","unstructured":"Ozdemir O, Calisaneller T, Sonmez E, Kiyici H, Caner H, Altinors N (2010) Topical use of colchicine to prevent spinal epidural fibrosis in rats. Neurol Res 32:1117\u20131120. https:\/\/doi.org\/10.1179\/016164110x12681290831487","journal-title":"Neurol Res"},{"key":"4694_CR59","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.3748\/wjg.v16.i23.2889","volume":"16","author":"S Muntoni","year":"2010","unstructured":"Muntoni S, Rojkind M, Muntoni S (2010) Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease. World J Gastroenterol 16:2889\u20132894. https:\/\/doi.org\/10.3748\/wjg.v16.i23.2889","journal-title":"World J Gastroenterol"},{"key":"4694_CR60","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.cgh.2011.05.010","volume":"9","author":"J Leung","year":"2011","unstructured":"Leung J, Bonis PA, Kaplan MM (2011) Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 9:776\u2013780. https:\/\/doi.org\/10.1016\/j.cgh.2011.05.010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4694_CR61","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mehy.2016.08.006","volume":"95","author":"N Nikolaidis","year":"2016","unstructured":"Nikolaidis N, Polyzos SA, Giouleme O et al (2016) Colchicine to decrease inflammation and fibrosis in patients with metabolic dysregulation. Med Hypotheses 95:34. https:\/\/doi.org\/10.1016\/j.mehy.2016.08.006","journal-title":"Med Hypotheses"},{"key":"4694_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.13842","author":"S Shah","year":"2020","unstructured":"Shah S, Das S, Jain A, Misra DP, Negi VS (2020) A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis. https:\/\/doi.org\/10.1111\/1756-185x.13842","journal-title":"Int J Rheum Dis"},{"key":"4694_CR63","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.3346\/jkms.2020.35.e231","volume":"35","author":"BY Ahn","year":"2020","unstructured":"Ahn BY, Kang CK, Seo JD et al (2020) A case of breakthrough COVID-19 during hydroxychloroquine maintenance. J Korean Med Sci 35:e231. https:\/\/doi.org\/10.3346\/jkms.2020.35.e231","journal-title":"J Korean Med Sci"},{"key":"4694_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2020.1792778","author":"SE Sattui","year":"2020","unstructured":"Sattui SE, Liew JW, Graef ER et al (2020) Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Rev Clin Immunol. https:\/\/doi.org\/10.1080\/1744666x.2020.1792778","journal-title":"Expert Rev Clin Immunol"},{"key":"4694_CR65","doi-asserted-by":"crossref","unstructured":"Gurjar M, Agarwal V (2020) Usefulness of hydroxychloroquine for COVID-19: does answer lie in timing to start? Indian J Rheumatol (epub ahead of print)","DOI":"10.4103\/injr.injr_167_20"},{"key":"4694_CR66","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/cbf.3182","volume":"34","author":"H Akpovwa","year":"2016","unstructured":"Akpovwa H (2016) Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. Cell Biochem Funct 34:191\u2013196. https:\/\/doi.org\/10.1002\/cbf.3182","journal-title":"Cell Biochem Funct"},{"key":"4694_CR67","doi-asserted-by":"publisher","first-page":"18132","DOI":"10.1021\/acsomega.8b01002","volume":"3","author":"A Kumar","year":"2018","unstructured":"Kumar A, Liang B, Aarthy M et al (2018) Hydroxychloroquine inhibits zika virus NS2B-NS3 protease. ACS Omega 3:18132\u201318141. https:\/\/doi.org\/10.1021\/acsomega.8b01002","journal-title":"ACS Omega"},{"key":"4694_CR68","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s10067-020-05247-5","volume":"39","author":"R Parra-Medina","year":"2020","unstructured":"Parra-Medina R, Sarmiento-Monroy JC, Rojas-Villarraga A, Garavito E, Montealegre-G\u00f3mez G, G\u00f3mez-L\u00f3pez A (2020) Colchicine as a possible therapeutic option in COVID-19 infection. Clin Rheumatol 39:2485\u20132486. https:\/\/doi.org\/10.1007\/s10067-020-05247-5","journal-title":"Clin Rheumatol"},{"key":"4694_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217712","author":"M Scarsi","year":"2020","unstructured":"Scarsi M, Piantoni S, Colombo E et al (2020) Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217712","journal-title":"Ann Rheum Dis"},{"key":"4694_CR70","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00296-020-04645-x","volume":"40","author":"F Haslak","year":"2020","unstructured":"Haslak F, Yildiz M, Adrovic A et al (2020) Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic. Rheumatol Int 40:1423\u20131431. https:\/\/doi.org\/10.1007\/s00296-020-04645-x","journal-title":"Rheumatol Int"},{"key":"4694_CR71","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13195-020-00640-3","volume":"12","author":"MT Heneka","year":"2020","unstructured":"Heneka MT, Golenbock D, Latz E, Morgan D, Brown R (2020) Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther 12:69. https:\/\/doi.org\/10.1186\/s13195-020-00640-3","journal-title":"Alzheimers Res Ther"},{"key":"4694_CR72","doi-asserted-by":"publisher","first-page":"W87","DOI":"10.1097\/RTI.0000000000000534","volume":"35","author":"S Salehi","year":"2020","unstructured":"Salehi S, Reddy S, Gholamrezanezhad A (2020) Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19): what we know and what to expect. J Thorac Imaging 35:W87\u2013W89","journal-title":"J Thorac Imaging"},{"key":"4694_CR73","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s10067-020-05275-1","volume":"39","author":"S Ahmed","year":"2020","unstructured":"Ahmed S, Zimba O, Gasparyan AY (2020) Thrombosis in coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad. Clin Rheumatol 39:2529\u20132543. https:\/\/doi.org\/10.1007\/s10067-020-05275-1","journal-title":"Clin Rheumatol"},{"key":"4694_CR74","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/14740338.2016.1175428","volume":"15","author":"B Grabias","year":"2016","unstructured":"Grabias B, Kumar S (2016) Adverse neuropsychiatric effects of antimalarial drugs. Expert Opin Drug Saf 15:903\u2013910. https:\/\/doi.org\/10.1080\/14740338.2016.1175428","journal-title":"Expert Opin Drug Saf"},{"key":"4694_CR75","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3346\/jkms.2017.32.3.522","volume":"32","author":"DR Eo","year":"2017","unstructured":"Eo DR, Lee MG, Ham DI et al (2017) Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases. J Korean Med Sci 32:522\u2013527. https:\/\/doi.org\/10.3346\/jkms.2017.32.3.522","journal-title":"J Korean Med Sci"},{"key":"4694_CR76","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386\u20131394. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.058","journal-title":"Ophthalmology"},{"key":"4694_CR77","doi-asserted-by":"publisher","unstructured":"Fiehn C, Ness T, Weseloh C, et al. (2020) Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. Z Rheumatol. https:\/\/doi.org\/10.1007\/s00393-020-00785-4(epub ahead of print)","DOI":"10.1007\/s00393-020-00785-4"},{"key":"4694_CR78","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/jac\/dkw591","volume":"72","author":"JW Mason","year":"2017","unstructured":"Mason JW (2017) Antimicrobials and QT prolongation. J Antimicrob Chemother 72:1272\u20131274. https:\/\/doi.org\/10.1093\/jac\/dkw591","journal-title":"J Antimicrob Chemother"},{"key":"4694_CR79","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4103\/injr.injr_130_19","volume":"15","author":"A Patil","year":"2020","unstructured":"Patil A, Jerang Y, Mathew J (2020) Hydroxychloroquine-induced auditory toxicity. Indian J Rheumatol 15:53\u201355","journal-title":"Indian J Rheumatol"},{"key":"4694_CR80","doi-asserted-by":"publisher","first-page":"94","DOI":"10.31138\/mjr.31.1.94","volume":"31","author":"DP Bogdanos","year":"2020","unstructured":"Bogdanos DP, Daniil Z, Zakynthinos E, Gourgoulianis K, Sakkas LI (2020) When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients? Mediterr J Rheumatol 31:94\u201397. https:\/\/doi.org\/10.31138\/mjr.31.1.94","journal-title":"Mediterr J Rheumatol"},{"key":"4694_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.06.002","author":"U Paliani","year":"2020","unstructured":"Paliani U, Cardona A (2020) COVID-19 and hydroxychloroquine: is the wonder drug failing? Eur J Intern Med. https:\/\/doi.org\/10.1016\/j.ejim.2020.06.002","journal-title":"Eur J Intern Med"},{"key":"4694_CR82","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologist 21:1471\u20131482. https:\/\/doi.org\/10.1634\/theoncologist.2015-0164","journal-title":"Oncologist"},{"key":"4694_CR83","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00296-020-04547-y","volume":"40","author":"JS Lee","year":"2020","unstructured":"Lee JS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S (2020) Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction. Rheumatol Int 40:765\u2013770. https:\/\/doi.org\/10.1007\/s00296-020-04547-y","journal-title":"Rheumatol Int"},{"key":"4694_CR84","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/1756-185x.13004","volume":"20","author":"S Ajmani","year":"2017","unstructured":"Ajmani S, Preet Singh Y, Prasad S et al (2017) Methotrexate-induced pancytopenia: a case series of 46 patients. Int J Rheum Dis 20:846\u2013851. https:\/\/doi.org\/10.1111\/1756-185x.13004","journal-title":"Int J Rheum Dis"},{"key":"4694_CR85","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/0973-3698.272161","volume":"14","author":"W-I Lee","year":"2019","unstructured":"Lee W-I, Hissaria P (2019) Drug-induced interstitial lung disease. Indian J Rheumatol 14:19\u201326. https:\/\/doi.org\/10.4103\/0973-3698.272161","journal-title":"Indian J Rheumatol"},{"key":"4694_CR86","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","volume":"57","author":"A Slobodnick","year":"2018","unstructured":"Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH (2018) Update on colchicine, 2017. Rheumatology (Oxford) 57:i4\u2013i11. https:\/\/doi.org\/10.1093\/rheumatology\/kex453","journal-title":"Rheumatology (Oxford)"},{"key":"4694_CR87","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00296-017-3823-1","volume":"38","author":"S Haj Yahia","year":"2018","unstructured":"Haj Yahia S, Ben Zvi I, Livneh A (2018) Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of Helicobacter pylori: a series of six patients. Rheumatol Int 38:141\u2013147. https:\/\/doi.org\/10.1007\/s00296-017-3823-1","journal-title":"Rheumatol Int"},{"key":"4694_CR88","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00296-019-04348-y","volume":"40","author":"R Tal","year":"2020","unstructured":"Tal R, Semo Oz R, Amarilyo G et al (2020) Safety and efficacy of intravenous colchicine in children with familial Mediterranean fever. Rheumatol Int 40:121\u2013128. https:\/\/doi.org\/10.1007\/s00296-019-04348-y","journal-title":"Rheumatol Int"},{"key":"4694_CR89","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00296-018-04237-w","volume":"39","author":"C Grossman","year":"2019","unstructured":"Grossman C, Farberov I, Feld O, Livneh A, Ben-Zvi I (2019) Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine. Rheumatol Int 39:517\u2013523. https:\/\/doi.org\/10.1007\/s00296-018-04237-w","journal-title":"Rheumatol Int"},{"key":"4694_CR90","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3109\/15563650.2010.495348","volume":"48","author":"Y Finkelstein","year":"2010","unstructured":"Finkelstein Y, Aks SE, Hutson JR et al (2010) Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) 48:407\u2013414. https:\/\/doi.org\/10.3109\/15563650.2010.495348","journal-title":"Clin Toxicol (Phila)"},{"key":"4694_CR91","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2174\/138161212799504759","volume":"18","author":"AY Gasparyan","year":"2012","unstructured":"Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD (2012) Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 18:1543\u20131555. https:\/\/doi.org\/10.2174\/138161212799504759","journal-title":"Curr Pharm Des"},{"key":"4694_CR92","doi-asserted-by":"publisher","unstructured":"Folegatti PM, Ewer KJ, Aley PK et al (2020) Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(20)31604-4.","DOI":"10.1016\/S0140-6736(20)31604-4"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04694-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-020-04694-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04694-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T18:29:21Z","timestamp":1744136961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-020-04694-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":92,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["4694"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04694-2","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"assertion":[{"value":"10 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Durga Prasanna Misra declares that he has no conflict of interest, including no relationship with pharmaceutical companies. Armen Yuri Gasparyan declares that he has no conflict of interest, including no relationship with pharmaceutical companies. Olena Zimba declares that she has no conflict of interest, including no relationship with pharmaceutical companies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}